ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 232,66
0,55%
Dow Jones
39 477,35
0,23%
DAX
18 778,55
0,53%
Brent Oil
83,755
-0,23%
Bitcoin
61 188,88
-2,89%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. LianBio (LIAN)

  7. LianBio (LIAN) Actualités

LIAN

LianBio (LIAN)

LianBio
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LIAN
DateHeureSourceTitreSymboleSociété
11/03/202412h51Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:LIANLianBio
28/02/202413h00GlobeNewswire Inc.LianBio Announces Voluntarily Delisting from NasdaqNASDAQ:LIANLianBio
20/02/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIANLianBio
13/02/202413h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIANLianBio
13/02/202413h00GlobeNewswire Inc.LianBio Announces Completion of Strategic ReviewNASDAQ:LIANLianBio
08/01/202412h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LIANLianBio
26/12/202322h10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LIANLianBio
26/12/202320h40AllPennyStocks.comBiotech Finds Success Following Holiday WeekendNASDAQ:LIANLianBio
26/12/202308h00GlobeNewswire Inc.LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsNASDAQ:LIANLianBio
20/12/202314h00GlobeNewswire Inc.LianBio Announces Departure of Chief Financial OfficerNASDAQ:LIANLianBio
19/12/202322h05GlobeNewswire Inc.LianBio Announces Departure of Chief Executive OfficerNASDAQ:LIANLianBio
06/12/202322h05GlobeNewswire Inc.LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesNASDAQ:LIANLianBio
01/12/202322h05GlobeNewswire Inc.LianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:LIANLianBio
13/11/202322h28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIANLianBio
13/11/202322h05GlobeNewswire Inc.LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LIANLianBio
30/10/202321h05GlobeNewswire Inc.LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisNASDAQ:LIANLianBio
25/10/202322h05GlobeNewswire Inc.LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023NASDAQ:LIANLianBio
24/10/202316h25AllPennyStocks.comBiotech Shares Soar PremarketNASDAQ:LIANLianBio
24/10/202315h22Dow Jones NewsLianBio Shares Soar Premarket on Strategic Review, End of Bristol PactNASDAQ:LIANLianBio
24/10/202312h59GlobeNewswire Inc.LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian MarketsNASDAQ:LIANLianBio
28/08/202322h05GlobeNewswire Inc.LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA CardiologyNASDAQ:LIANLianBio
14/08/202322h05GlobeNewswire Inc.LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LIANLianBio
03/08/202322h05GlobeNewswire Inc.LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsNASDAQ:LIANLianBio
26/07/202314h30GlobeNewswire Inc.LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex BlepharitisNASDAQ:LIANLianBio
18/07/202314h00GlobeNewswire Inc.LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and ThailandNASDAQ:LIANLianBio
17/07/202312h00GlobeNewswire Inc.LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023NASDAQ:LIANLianBio
12/07/202314h00GlobeNewswire Inc.LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsNASDAQ:LIANLianBio
26/06/202314h00GlobeNewswire Inc.LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in SingaporeNASDAQ:LIANLianBio
23/06/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LIANLianBio
23/06/202322h18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LIANLianBio
 Showing the most relevant articles for your search:NASDAQ:LIAN

Dernières Valeurs Consultées

EU
EN
Bouygues
EU
BN
Danone
EU
ML
Michelin
EU
RNO
Renault
EU
SGO
Cie de SaintGobain
NASDAQ
NVDA
NVIDIA
EU
MC
Lvmh Moet Hennessy Louis...
EU
PX4
SBF 120
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
EU
GLE
Societe Generale
EU
VK
Vallourec
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés